Stands up to White House’s strong-arm tactics against manufacturers of generic equivalent
Over the summer one thing about U.S. President Barack Obama has become clear. His hawkishness in foreign policy affects not only nations like Pakistan and Yemen, which are saddled with U.S. drones carrying out targeted assassinations on their soil. India too is very much a victim of Mr. Obama’s harshest policy campaigns, albeit in a less headline-grabbing area: cancer medication pricing.

A third of malaria drugs used around the world to keep the spread of the disease at bay are counterfeit, recent data has suggested. According to a study published in the reputed journal the Lancet, around 7 per cent of the drugs tested in India was found to be of poor quality with many being fake.
Researchers who looked at 1,500 samples of seven malaria drugs from seven countries in Southeast Asia said poor-quality and fake tablets are causing drug resistance and treatment failure. “Much of this morbidity and mortality could be avoided if drugs available to patients were efficacious, high quality, and used correctly,” said the Lancet.

Over a third of the Indian pharmacies continue to sell to livestock farmers the banned killer drug, diclofenac, responsible for the dramatic fall in vulture population in the country.
A study published

One hundred and forty nine farmer families in the Polonnaruwa District are being helped under a new community project of GlaxoSmithKline (GSK), to make the transition to better housing after their homes

In principle, generic pharma production could supply developing countries with all the drugs they need. In practice, matters are more difficult. Zafrullah Chowdhury shed light on this complex matter in an interview with Hans Dembowski.